A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2

By sjmartinez • February 27, 2024

Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, Davey RT Jr, Lye DC, Dodd LE, Yang OO, Benson CA, Deye GA, Doernberg SB, Hynes NA, Grossberg R, Wolfe CR, Nayak SU, Short WR, Voell J, Potter GE, Rapaka RR. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Ann Intern Med. 2024 Feb 27. doi: 10.7326/M23-2593. Epub ahead of print. PMID: 38408357.

Tags: Infectious Diseases, Publications

Related Posts

PenA Alleles Associated With Gonococcal Ceftriaxone Resistance in Cambodia, China, and Vietnam

van der Veen S, Sun X, Ge H, Chau TM, Nhung PH, Vandelannoote K, Delvallez G, Cheng S, Laumen JGE, Adamson PC. PenA Alleles Associated[...]

Cefixime for the Treatment of Neisseria gonorrhoeae Infections in a Setting With Increased Antimicrobial Resistance: A Retrospective Study in Hanoi, Vietnam

Adamson PC, David HM, Pham LQ, Bui HTM, Le HHL, Pham QH, Le DH, Giang LM, Klausner JD. Cefixime for the Treatment of Neisseria gonorrhoeae[...]

cGAS-STING dependent type I IFN reduces Leptospira interrogans renal colonization in mice

Gupta S, Matsunaga J, Ratitong B, Manion A, Ismaeel S, Valadares DG, West AP, Kerur N, Stehlik C, Dorfleutner A, Dagvadorj J, Coburn J, Wolf[...]